![At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma](https://oncodaily.com/pub/uploads/2023/10/download-168-1280x1280.jpg)
Photo taken from Agenus/LinkedIn
Oct 23, 2023, 13:31
At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma
Agenus shared on their LinkedIn page:
“At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab (BOT/BAL) combination in relapsed/refractory sarcoma, which showed durable responses across multiple subtypes. The results reinforce the potential of BOT/BAL in multiple cold, treatment-resistant solid tumors. Learn more here.”
Source: Agenus/LinkedIn